Phase 2 Endometrial Cancer Trial, Recruiting NCT07055399 Sponsor: Fujian Cancer Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT07055399
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 70 years old
  • People who have signed a written agreement to take part in the study
  • People whose heart, liver, kidneys, and other major organs are working well enough, and who are generally well enough to carry out light activity or normal daily tasks (ECOG score of 0 or 1)
  • People who have not received any systemic treatment for their condition at the time of joining the study
  • People whose cervical cancer has been classified as stage IB3, IIA2, or IIIC1r using the FIGO 2018 staging system (confirm with trial site)
  • People whose cancer has been confirmed by a tissue sample (biopsy) to be squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
  • People whose cancer has at least one area that can be measured using standard imaging guidelines (RECIST v1.1)
  • People who are willing to have blood and tumour tissue samples collected and tested
  • People whose blood test results meet specific levels, including haemoglobin, white blood cells, and platelets, without having had a blood transfusion in the 14 days before testing (confirm with trial site for exact values)
  • People whose liver function blood test results fall within acceptable ranges for certain markers (confirm with trial site for exact values)
  • People who are able and willing to attend all scheduled visits, follow the study plan, and complete all required tests and procedures

Who may not be able to join:

  • People who have had another cancer diagnosis within the past 3 years
  • People who are currently taking part in another clinical trial
  • People who have an autoimmune disease that currently requires ongoing systemic (whole-body) treatment
  • People who have an active infection that currently requires ongoing systemic treatment
  • People who have previously had a transplant of tissue or a solid organ from another person
  • People with serious health conditions, such as severe mental health disorders, heart disease, blood clotting problems, or serious digestive system conditions
  • People with an active hepatitis B, hepatitis C, or HIV infection
  • People who are pregnant or currently breastfeeding
  • People with a current problem with drug or alcohol misuse
  • People who are unable or unwilling to sign the informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-15959028989

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Fujian Cancer Hospital
Registry
ClinicalTrials.gov
Start date
21 August 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological complete response (pCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov